Compare
SS-31 vs Tirzepatide
Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.
Observational reporting only — not medical advice. Does not recommend doses, protocols, or treatments.
SS-31
58 community reports
Positive 2% · Neutral 2% · Negative 96%
Most reported benefits
Energy
187
Most reported side effects
Injection site irritation
183
Dose distribution
Median: 2000+ mcg · Most common: 2000+ mcg
0–25
0
25–50
10
50–100
0
100–200
0
200–400
2
400–600
1
600–1000
4
1000–2000
18
2000+
151
Commonly stacked with
How repeat users are trending
Among repeat reporters, 92% said they felt similar to their last entry, 8% more positive, and 0% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 73 days · Based on 37 repeat reporters
Tirzepatide
6 community reports
Positive 0% · Neutral 0% · Negative 100%
Most reported benefits
Appetite
6
Most reported side effects
Nausea
3
Injection site irritation
3
Dose distribution
Median: 2000+ mcg · Most common: 2000+ mcg
0–25
0
25–50
0
50–100
0
100–200
0
200–400
0
400–600
1
600–1000
0
1000–2000
0
2000+
5